Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
Authors:
Open Access
- 28 May 2025
- journal article
- Published by Elsevier in Annals of Oncology
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapseAnnals of Oncology, 2024
- Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trialAnnals of Oncology, 2022
- Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Surgical management of metastatic gastrointestinal stromal tumourEuropean Journal of Surgical Oncology, 2018
- Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsJAMA Oncology, 2017
- Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinibCancer, 2015
- Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in ChinaEuropean Journal of Cancer, 2014
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal of Cancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001